Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This is a phase I study. The purpose of this study is to see if it is safe and feasible to give the participant cyclophosphamide (a type of chemotherapy), natural killer (NK) cells, and an antibody called Hu3F8 as a treatment for neuroblastoma. NK cells are a type of white blood cell.
Funding Source- FDA OOPD
Enrollment
Sex
Volunteers
Inclusion criteria
Donor Inclusion Criteria
Exclusion criteria
Donor Exclusion Criteria:
Primary purpose
Allocation
Interventional model
Masking
85 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal